Regeneron Pharmaceuticals, Inc. (REGN)
$778.36+3.35%Close
SELLRECOVERY · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV8.4%–80.8%
- Market cap
- $80.2B
- Beta
- 0.24
- Div yield
- 0.48%
- P/E (TTM)
- 18.59
- IV-%ile
- 12
- IV ATM
- 25.5%
- Short % float
- 2.13%
- Days to cover
- 2.5
- SI change
- -14.9%
- 1W
- +4.88%
- 1M
- +0.55%
- vs SPY 1W
- +5.86%
- vs SPY 1M
- -1.32%
Industry peers
FMP comparable companies · ranked by market cap
- NVSBUYNovartis AG$273.2BRECOVERYQ 20$143.75+3.14%
- AZNSELLAstraZeneca PLC$246.9BRECOVERYQ 20$159.20+3.99%
- AMGNBUYAmgen Inc.$223.9BRECOVERYQ 22$414.87+3.21%
- GILDBUYGilead Sciences, Inc.$187.4BBULLQ 25$151.17+3.80%
- BIIBBUYBiogen Inc.$33.3BBULLQ 19$225.71+1.72%
- GMABBUYGenmab A/S$22.8BBULLQ 21$37.07+0.88%
- IVBXFInnovent Biologics, Inc.$21.1B$12.14
- REGMFRemeGen Co., Ltd.$5.6B$9.96
- OCULSELLOcular Therapeutix, Inc.$1.7BCRISISQ 3$7.54-0.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on REGN?
- LOPJLB’s latest quantitative signal on Regeneron Pharmaceuticals, Inc. (REGN) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is REGN in?
- Regeneron Pharmaceuticals, Inc. (REGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Regeneron Pharmaceuticals, Inc. (REGN) do?
- Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neo…